Abstract

Background: Increasing evidence of cure for some neoplasms has emerged in recent years. The study aimed to estimate population-based indicators of cancer cure. Methods: Information on more than half a million cancer patients aged 15-74 years collected by population-based Italian cancer registries and mixture cure models were used to estimate the life expectancy of fatal tumors (LEFT), proportions of patients with similar death rates of the general population (cure fraction), and time to reach 5-year conditional relative survival (CRS) >90% or 95% (time to cure). Results: Between 1990 and 2000, the median LEFT increased >1 year for breast (from 8.1 to 9.4 years) and prostate cancers (from 5.2 to 7.4 years). Median LEFT in 1990 was >5 years for testicular cancers (5.8) and Hodgkin lymphoma (6.3) below 45 years of age. In both sexes, it was ≤0.5 years for pancreatic cancers and NHL in 1990 and in 2000. The cure fraction showed a 10% increase between 1990 and 2000. It was 95% for thyroid cancer in women, 94% for testis, 75% for prostate, 67% for breast cancers, and <20% for liver, lung, and pancreatic cancers. Time to 5-year CRS >95% was <10 years for testis, thyroid, colon cancers, and melanoma. For breast and prostate cancers, the 5-year CRS >90% was reached in <10 years but a small excess remained for >15 years. Conclusions: The study findings confirmed that several cancer types are curable. Became aware of the possibility of cancer cure has relevant clinical and social impacts.

Original languageEnglish
Pages (from-to)4497-4507
Number of pages11
JournalCancer Medicine
Volume8
Issue number9
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Survivors
Population
Neoplasms
Life Expectancy
Testicular Neoplasms
Social Change
Hodgkin Disease
Thyroid Neoplasms
Registries
Testis
Prostate
Prostatic Neoplasms
Breast
Breast Neoplasms
Survival
Mortality

Keywords

  • cancer cure
  • Italy
  • population-based cancer registries
  • prevalence
  • survival

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Prognosis and cure of long-term cancer survivors : A population-based estimation. / AIRTUM Working Group.

In: Cancer Medicine, Vol. 8, No. 9, 01.01.2019, p. 4497-4507.

Research output: Contribution to journalArticle

AIRTUM Working Group. / Prognosis and cure of long-term cancer survivors : A population-based estimation. In: Cancer Medicine. 2019 ; Vol. 8, No. 9. pp. 4497-4507.
@article{0f72363d8e6a4baca16bd5f20f9e76aa,
title = "Prognosis and cure of long-term cancer survivors: A population-based estimation",
abstract = "Background: Increasing evidence of cure for some neoplasms has emerged in recent years. The study aimed to estimate population-based indicators of cancer cure. Methods: Information on more than half a million cancer patients aged 15-74 years collected by population-based Italian cancer registries and mixture cure models were used to estimate the life expectancy of fatal tumors (LEFT), proportions of patients with similar death rates of the general population (cure fraction), and time to reach 5-year conditional relative survival (CRS) >90{\%} or 95{\%} (time to cure). Results: Between 1990 and 2000, the median LEFT increased >1 year for breast (from 8.1 to 9.4 years) and prostate cancers (from 5.2 to 7.4 years). Median LEFT in 1990 was >5 years for testicular cancers (5.8) and Hodgkin lymphoma (6.3) below 45 years of age. In both sexes, it was ≤0.5 years for pancreatic cancers and NHL in 1990 and in 2000. The cure fraction showed a 10{\%} increase between 1990 and 2000. It was 95{\%} for thyroid cancer in women, 94{\%} for testis, 75{\%} for prostate, 67{\%} for breast cancers, and <20{\%} for liver, lung, and pancreatic cancers. Time to 5-year CRS >95{\%} was <10 years for testis, thyroid, colon cancers, and melanoma. For breast and prostate cancers, the 5-year CRS >90{\%} was reached in <10 years but a small excess remained for >15 years. Conclusions: The study findings confirmed that several cancer types are curable. Became aware of the possibility of cancer cure has relevant clinical and social impacts.",
keywords = "cancer cure, Italy, population-based cancer registries, prevalence, survival",
author = "{AIRTUM Working Group} and {Dal Maso}, Luigino and Chiara Panato and Stefano Guzzinati and Diego Serraino and Silvia Francisci and Laura Botta and Riccardo Capocaccia and Andrea Tavilla and Anna Gigli and Emanuele Crocetti and Massimo Rugge and Giovanna Tagliabue and Filiberti, {Rosa Angela} and Giuliano Carrozzi and Maria Michiara and Stefano Ferretti and Rosaria Cesaraccio and Rosario Tumino and Fabio Falcini and Fabrizio Stracci and Antonietta Torrisi and Guido Mazzoleni and Mario Fusco and Stefano Rosso and Francesco Tisano and Fanetti, {Anna Clara} and Sini, {Giovanna Maria} and Carlotta Buzzoni and {De Angelis}, Roberta and Saverio Virdone and Gemma Gatta and Manuel Zorzi and Sandra Mallone and Federica Toffolutti and Russo, {Antonio Giampiero} and Caiazzo, {Anna Luisa} and Lucia Mangone and Walter Mazzucco and Fabio Pannozzo and Paolo Ricci and Gemma Gola and Giuseppa Candela and {Sutera Sardo}, Antonella",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/cam4.2276",
language = "English",
volume = "8",
pages = "4497--4507",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Prognosis and cure of long-term cancer survivors

T2 - A population-based estimation

AU - AIRTUM Working Group

AU - Dal Maso, Luigino

AU - Panato, Chiara

AU - Guzzinati, Stefano

AU - Serraino, Diego

AU - Francisci, Silvia

AU - Botta, Laura

AU - Capocaccia, Riccardo

AU - Tavilla, Andrea

AU - Gigli, Anna

AU - Crocetti, Emanuele

AU - Rugge, Massimo

AU - Tagliabue, Giovanna

AU - Filiberti, Rosa Angela

AU - Carrozzi, Giuliano

AU - Michiara, Maria

AU - Ferretti, Stefano

AU - Cesaraccio, Rosaria

AU - Tumino, Rosario

AU - Falcini, Fabio

AU - Stracci, Fabrizio

AU - Torrisi, Antonietta

AU - Mazzoleni, Guido

AU - Fusco, Mario

AU - Rosso, Stefano

AU - Tisano, Francesco

AU - Fanetti, Anna Clara

AU - Sini, Giovanna Maria

AU - Buzzoni, Carlotta

AU - De Angelis, Roberta

AU - Virdone, Saverio

AU - Gatta, Gemma

AU - Zorzi, Manuel

AU - Mallone, Sandra

AU - Toffolutti, Federica

AU - Russo, Antonio Giampiero

AU - Caiazzo, Anna Luisa

AU - Mangone, Lucia

AU - Mazzucco, Walter

AU - Pannozzo, Fabio

AU - Ricci, Paolo

AU - Gola, Gemma

AU - Candela, Giuseppa

AU - Sutera Sardo, Antonella

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Increasing evidence of cure for some neoplasms has emerged in recent years. The study aimed to estimate population-based indicators of cancer cure. Methods: Information on more than half a million cancer patients aged 15-74 years collected by population-based Italian cancer registries and mixture cure models were used to estimate the life expectancy of fatal tumors (LEFT), proportions of patients with similar death rates of the general population (cure fraction), and time to reach 5-year conditional relative survival (CRS) >90% or 95% (time to cure). Results: Between 1990 and 2000, the median LEFT increased >1 year for breast (from 8.1 to 9.4 years) and prostate cancers (from 5.2 to 7.4 years). Median LEFT in 1990 was >5 years for testicular cancers (5.8) and Hodgkin lymphoma (6.3) below 45 years of age. In both sexes, it was ≤0.5 years for pancreatic cancers and NHL in 1990 and in 2000. The cure fraction showed a 10% increase between 1990 and 2000. It was 95% for thyroid cancer in women, 94% for testis, 75% for prostate, 67% for breast cancers, and <20% for liver, lung, and pancreatic cancers. Time to 5-year CRS >95% was <10 years for testis, thyroid, colon cancers, and melanoma. For breast and prostate cancers, the 5-year CRS >90% was reached in <10 years but a small excess remained for >15 years. Conclusions: The study findings confirmed that several cancer types are curable. Became aware of the possibility of cancer cure has relevant clinical and social impacts.

AB - Background: Increasing evidence of cure for some neoplasms has emerged in recent years. The study aimed to estimate population-based indicators of cancer cure. Methods: Information on more than half a million cancer patients aged 15-74 years collected by population-based Italian cancer registries and mixture cure models were used to estimate the life expectancy of fatal tumors (LEFT), proportions of patients with similar death rates of the general population (cure fraction), and time to reach 5-year conditional relative survival (CRS) >90% or 95% (time to cure). Results: Between 1990 and 2000, the median LEFT increased >1 year for breast (from 8.1 to 9.4 years) and prostate cancers (from 5.2 to 7.4 years). Median LEFT in 1990 was >5 years for testicular cancers (5.8) and Hodgkin lymphoma (6.3) below 45 years of age. In both sexes, it was ≤0.5 years for pancreatic cancers and NHL in 1990 and in 2000. The cure fraction showed a 10% increase between 1990 and 2000. It was 95% for thyroid cancer in women, 94% for testis, 75% for prostate, 67% for breast cancers, and <20% for liver, lung, and pancreatic cancers. Time to 5-year CRS >95% was <10 years for testis, thyroid, colon cancers, and melanoma. For breast and prostate cancers, the 5-year CRS >90% was reached in <10 years but a small excess remained for >15 years. Conclusions: The study findings confirmed that several cancer types are curable. Became aware of the possibility of cancer cure has relevant clinical and social impacts.

KW - cancer cure

KW - Italy

KW - population-based cancer registries

KW - prevalence

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85070230973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070230973&partnerID=8YFLogxK

U2 - 10.1002/cam4.2276

DO - 10.1002/cam4.2276

M3 - Article

C2 - 31207165

AN - SCOPUS:85070230973

VL - 8

SP - 4497

EP - 4507

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 9

ER -